Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abilify Review Shows FDA Debate Over QTc Methods Of Analysis

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA’s review of Bristol-Myers Squibb/Otsuka’s atypical antipsychotic Abilify suggests that the method of analysis used to detect QT prolongation is key to the results.

You may also be interested in...



Abilify Comparative Safety Claims Require Least Favorable Dose Comparison

Comparative safety claims for Bristol-Myers Squibb/Otsuka’s atypical antipsychotic Abilify would require studies comparing the highest dose of aripiprazole to the lowest dose of the comparator or a more complicated multi-dose comparative trial, FDA review documents show.

Abilify Comparative Safety Claims Require Least Favorable Dose Comparison

Comparative safety claims for Bristol-Myers Squibb/Otsuka’s atypical antipsychotic Abilify would require studies comparing the highest dose of aripiprazole to the lowest dose of the comparator or a more complicated multi-dose comparative trial, FDA review documents show.

Lilly Avoids Strattera Risk Management Program; QTc Key Concern In Review

Lilly’s response to an "approvable" letter for Strattera allowed the company to avoid a label requirement to test for poor metabolizers of the drug, as well as a related warning on QTc prolongation, review documents indicate.

Topics

UsernamePublicRestriction

Register

PS002233

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel